Concepta PLC Concepta to supply myLotus® to Boots UK (3750U)
March 29 2019 - 3:00AM
UK Regulatory
TIDMCPT
RNS Number : 3750U
Concepta PLC
29 March 2019
Concepta to supply myLotus(R) to Boots UK
Concepta Plc (AIM: CPT), the innovative UK personalised
healthcare company and developer of the proprietary self-test
platform ("myLotus(R)") and suite of emerging test products
targeting the mobile health market, is pleased to announce it has
agreed to supply the myLotus(R) product for women's fertility and
hormone testing to Boots UK, a member of Walgreens Boots
Alliance.
myLotus(R) the revolutionary home based, self-test product was
launched in November 2018 with early 'trying to conceive' users
providing personal video feedback and testimonials on their
menstrual cycle hormone changes and hormone patterns ('signatures')
enabling women to better understand their menstrual cycle and
fertility journey (www.mylotus.com).
The Boots supply agreement represents the first commercial
partnership forming part of the Company's EU roll-out plans.
myLotus(R) recently received CE-Mark certification and the
agreement allows the Company to sell its product online at
www.Boots.com as well as to other partners across EU markets
(CE-Mark territories).
myLotus(R) empowers women to self-test their personalised
hormone levels and identify their optimal fertile days thereby
improving their chances of naturally getting pregnant. myLotus(R)
enables women to monitor their fertile phase as part of their
menstrual cycle and is the only home test to 'quantitatively'
measure hormone levels and the 'rate-of-change' of these levels
preceding ovulation to help aid a natural conception. Users
measure, record and track their hormone levels and follow their
fertility journey in an accompanying free downloadable app
available in iOS and Android formats via the www.mylotus.com
website.
myLotus(R) is available to women who are planning to start a
family or for those who have previously struggled to naturally
conceive, enabling couples an alternative prior to considering more
costly IVF treatment. The Company expects to release further
hormone health and wellbeing tests to complement its fertility
offering later this year.
Matthew Walls, Chairman said: "We are delighted to work with
such a respected British high-street brand and retailer and look
forward to supplying myLotus(R) to Boots UK to help improve the
chances of a natural pregnancy. We are now preparing our EU market
roll-out plans and awaiting our first pregnancies and will update
the market in due course"
Enquiries
Company: www.conceptaplc.com, Product: www.mylotus.com
Matthew Walls, Chairman
Tel: +44 (0) 1234 866601
SPARK Advisory Partners Limited (Nomad)
Neil Baldwin
Tel: +44 (0)20 368 3550
Novum Securities
Colin Rowbury
+44 (0) 20 7399 9400
About Concepta Plc:
Concepta Plc is an AIM-quoted pioneering UK healthcare company
that has developed a proprietary product, myLotus(R), targeting the
personalised mobile health market with a primary focus on hormone
testing and increasing a woman's chances of naturally getting
pregnant. myLotus also provides an insight to unexplained
infertility.
myLotus(R) is currently the only consumer product which allows
both quantitative and qualitative home (self-test) test measurement
of a woman's personal luteinizing hormone (LH) during ovulation and
human chorionic gonadotropin (hCG) hormone level during pregnancy,
facilitating higher conception rates and early diagnosis of
fertility issues. The proposition of myLotus(R) is to empower women
to better understand their hormone levels and menstrual cycle and
help women conceive naturally by identifying their window of
fertility and optimal time for conception.
The Company has received CE-mark certification for myLotus(R)
and has launched its first product in the UK. The Company is
preparing plans to roll-out across the core EU countries in
2019.
myLotus(R) is expected to be beneficial to users who have been
unable to conceive after 6 months of trying. This highly motivated
target group of women won't typically be offered medical
intervention until after 12 months of unsuccessfully trying to
conceive, with IVF not usually offered until after two years of
trying to conceive. Research indicates couples start to take
positive action ahead of this time typically with little medical
support to help them do so.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRCKFDBPBKDKNB
(END) Dow Jones Newswires
March 29, 2019 03:00 ET (07:00 GMT)
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From Apr 2023 to Apr 2024